Announcements
- Bavarian Nordic Submits Supplemental BLA Seeking U.S. FDA Approval of Freeze-Dried Formulation of Smallpox and Mpox Vaccine
- Bavarian Nordic indsender supplerende ansøgning til de amerikanske sundhedsmyndigheder om godkendelse af frysetørret koppe- og mpoxvaccine
- Bavarian Nordic og CEPI indgår partnerskab om mpox-vaccinationer i Afrika
- Bavarian Nordic and CEPI Partners to Advance Mpox Vaccination in Africa
- Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise
- Kapitalforhøjelse i Bavarian Nordic A/S som følge af medarbejderes udnyttelse af tegningsoptioner
- Bavarian Nordic – transaktioner i forbindelse med aktietilbagekøbsprogram samt ophør af aktietilbagekøbsprogram
- Bavarian Nordic – Transactions in Connection with Share Buy-Back Program and Termination of Share Buy-Back Program
- Laurence de Moerlooze fratræder som EVP og Chief Medical Officer i Bavarian Nordic
- EVP and Chief Medical Officer Laurence de Moerlooze Will Be Leaving Bavarian Nordic
More ▼
Key statistics
On Thursday, Bavarian Nordic A/S (BV3:DUS) closed at 22.13, 31.61% above the 52 week low of 16.82 set on Oct 25, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 23.06 |
---|---|
High | 23.06 |
Low | 22.13 |
Bid | -- |
Offer | -- |
Previous close | 22.13 |
Average volume | 419.40 |
---|---|
Shares outstanding | 78.12m |
Free float | 78.05m |
P/E (TTM) | 13.31 |
Market cap | 13.37bn DKK |
EPS (TTM) | 12.86 DKK |
Data delayed at least 15 minutes, as of Jun 13 2024 18:31 BST.
More ▼